Literature DB >> 3459463

Induction of differentiation in the human promyelocytic leukemia cell line HL-60 by the cyclopentenyl analogue of cytidine.

R I Glazer, M B Cohen, K D Hartman, M C Knode, M I Lim, V E Marquez.   

Abstract

The effects of the cyclopentenyl (cCyd) and cyclopentyl (carbodine) analogues of cytidine on differentiation, and nucleic acid and nucleotide biosynthesis, were examined in the human promyelocytic leukemia cell line HL-60. Continuous exposure for 5 days to 10(-8) to 10(-6) M cCyd or 10(-6) to 10(-5) M carbodine produced progressive inhibition of cell growth. During this exposure interval, pronounced differentiation to mature myeloid cells occurred wherein 95% of the cell population reduced nitroblue tetrazolium 4 days after exposure to 10(-7) M cCyd or 10(-5) M carbodine. Preceding differentiation was the inhibition of DNA synthesis which reached 10% of control levels 24 hr after exposure to 10(-7) M cCyd or 10(-5) M carbodine, while RNA synthesis was inhibited to a lesser extent. The induction of mature myeloid cells by cCyd was preceded by the inhibition of c-myc mRNA levels which was more pronounced than the reduction in total cellular RNA synthesis. During the interval of cCyd treatment, there was a rapid and pronounced inhibition in the level of CTP, but not of UTP, ATP or GTP, where the half-life for the disappearance of CTP was 1.5 to 2 hr. Following drug removal, cells treated with cCyd showed a sustained reduction in CTP levels, whereas cells treated with carbodine showed almost complete recovery of CTP levels within 48 hr. These results indicate that the reduction in CTP levels leads to rapid inhibition of DNA synthesis and reduction in c-myc mRNA levels which precede the appearance of differentiated cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3459463     DOI: 10.1016/0006-2952(86)90301-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Cyclopentenyl cytosine: interspecies predictions based on rodent plasma and urine kinetics.

Authors:  D S Zaharko; J A Kelley; J E Tomaszewski; L Hegedus; N R Hartman
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

2.  In vitro characterization of the myelotoxicity of cyclopentenyl cytosine.

Authors:  D A Volpe; D L Du; C K Grieshaber; M J Murphy
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Phase I clinical trial of continuous infusion cyclopentenyl cytosine.

Authors:  P M Politi; F Xie; W Dahut; H Ford; J A Kelley; A Bastian; A Setser; C J Allegra; A P Chen; J M Hamilton
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine.

Authors:  E De Clercq; R Bernaerts; Y F Shealy; J A Montgomery
Journal:  Biochem Pharmacol       Date:  1990-01-15       Impact factor: 5.858

5.  Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase.

Authors:  E De Clercq; J Murase; V E Marquez
Journal:  Biochem Pharmacol       Date:  1991-06-15       Impact factor: 5.858

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.